MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1874647

Медицинская библиотека · Frontiers in immunology · 2026

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.

Zhang Wei, Wei Chen, Huang Haitao, Wang Xue, Xie Zhiqiang, Wu Yan, Wang Feiyu, Huang Lili, Wang Xuewen, Sui Xiuwen, Wan Peng, Chao Zhe, Gou Jinbo, Shi Bozhi, Liu Jia, Zhu Tao, Yuan Liyong, Wang Yanxia

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

UNLABELLED: This study aimed to evaluate the safety and immunogenicity of a novel diphtheria, tetanus, and pertussis (acellular, three components) combined vaccine, adsorbed (DTcP) vaccine compared to the existing co-purified DTaP vaccine in China. In this partially randomized, blinded, controlled Phase III trial, we assessed a DTcP vaccine against two controls: a licensed co-purified DTaP and a DTaP-IPV-Hib vaccine. A total of 1,140 infants (3 months old) received a 3-dose primary series at 3, 4, and 5 months. Both of DTcP and co-purified DTaP had lower incidences of overall adverse reactions than the DTaP-IPV-Hib vaccine (17.99%/18.08% vs. 21.96%). The DTcP vaccine demonstrated non-inferiority and superiority over the co-purified DTaP for anti-PT and anti-FHA immunogenicity. In addition, the DTcP achieved a 98.16% seroconversion rate for anti-FHA, versus only 14.29% for the co-purified DTaP. Besides, DTcP vaccine also induced high antibody level in GMC results. Specifically, the anti-PT GMC was 85.10 in the DTcP group versus 49.86 in the DTaP group (P < 0.001) and 74.25 in the DTaP-IPV-Hib (P = 0.001). For anti-FHA, the GMC was 108.28 in the DTcP group compared to only 10.69 in the DTaP group. In conclusion, DTcP vaccine induces a significantly more robust immune response to key pertussis antigens --compared to the co-purified DTaP, with a comparable safety profile. These data support the potential optimization of China's immunization strategy by transitioning from co-purified to component-based acellular pertussis vaccines to address waning immunity and the ongoing pertussis resurgence.

CLINICAL TRIAL REGISTRATION: ClinicalTrial.gov, identifier NCT05951725.

Для цитирования: Zhang Wei, Wei Chen, Huang Haitao, Wang Xue, Xie Zhiqiang, Wu Yan, Wang Feiyu, Huang Lili, Wang Xuewen, Sui Xiuwen, Wan Peng, Chao Zhe, Gou Jinbo, Shi Bozhi, Liu Jia, Zhu Tao, Yuan Liyong, Wang Yanxia. Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1874647.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.